Trending
News
Mabion S.A. completes marketing authorization application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)
Plexus Ventures would like to share successful news from Mabion S.A. Additional details are provided in Mabion’s press release (Konstantynów Łódzki, 1.06.2018): • Company submitted the marketing authorization application under the centralized authorization procedure...
Plexus Ventures Assists Fujifilm Kyowa Kirin Biologics in Partnering with Mylan of Humira® Biosimilar
Tokyo, Japan – Plexus Ventures is pleased to announce the successful conclusion of an out-licensing project of its client Fujifilm Kyowa Kirin Biologics Co., Ltd. Plexus Ventures provided professional services to Fujifilm Kyowa Kirin Biologics to partner the European...
Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex® on Scandinavian markets
Plexus Ventures would like to share successful news from Celon Pharma. Additional details are provided in Celon’s press release (Warsaw, 30.11.2017): • Finalisation of the DCP opens new perspectives for the Company in terms of export to the market as big as approx. 3...
Plexus Ventures Assists Celon Pharma SA with Development Strategy
Philadelphia, PA - Plexus Ventures, a global pharmaceutical consulting firm, announces its collaboration with Celon Pharma SA, Łomianki, Poland. Michael O’Sullivan Managing Partner London Office, noted: “We are very pleased to provide continuing support to an...
Plexus Ventures Assists Sylphar with Vendis Capital Investment, Enabling Concordia Fund Exit
Philadelphia, Pennsylvania - Plexus Ventures is pleased to announce it assisted the successful completion of a transaction in which Vendis Capital, a European private equity fund specialized in the consumer brands sector, invested in Sylphar, a fast-growing, Belgian...
Fujifilm Kyowa Kirin Biologics Announces EMA Acceptance to Review Biosimilar FKB327
Philadelphia, PA – Plexus Ventures is pleased to announce that its client, Fujifilm Kyowa Kirin Biologics (FKB), has confirmed that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application for FKB327 (adalimumab biosimilar)....
Healthware Group and Plexus Ventures Form Alliance to Accelerate Partnerships Between Digital Therapeutics & Pharma
Milan and New York, 16/2/2021 – Healthware Group and Plexus Ventures have formed an alliance to structure deals for the pharmaceutical industry in the development and commercialization of DTx products. Given the increased attention and growth seen in the market, both...
Plexus Ventures Assists Glenmark Pharmaceuticals to Out-License Ryaltris™ Nasal Spray to Menarini for numerous markets throughout Europe
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Glenmark Pharmaceuticals. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal...
How can we help you?
Plexus Ventures assists with M&A, divestments, licensing, strategic advice and consulting.
Subscribe to
Plexus News
Follow Us
Check out Plexus Ventures and other industry news shared daily.